Blauvelt A, et al. - Authors assessed the effectiveness of certolizumab pegol, an Fc-free, PEGylated, anti-tumor necrosis factor (TNF) biologic, in selected subgroups of adult patients with moderate-to-severe chronic plaque psoriasis in this pooled analysis of week 16 data from three randomized controlled trials. In patients with and without prior biologic therapy, results demonstrated an association of certolizumab pegol 400 mg or 200 mg every 2 weeks for 16 weeks with statistically significant and clinically meaningful improvements in signs and symptoms of psoriasis, and a safety profile consistent with the anti-TNF class in psoriasis.